A5076073861- Cervical Cancer and HPV Research
- Global Cancer Incidence and Screening
- Genital Health and Disease
- Hepatitis B Virus Studies
- Viral-associated cancers and disorders
- Colorectal Cancer Screening and Detection
- AI in cancer detection
- Radiomics and Machine Learning in Medical Imaging
- Endometrial and Cervical Cancer Treatments
- Advances in Oncology and Radiotherapy
- Diversity and Career in Medicine
- Family Support in Illness
- HIV/AIDS Research and Interventions
- Global Health and Surgery
- Global Health Workforce Issues
- Economic and Financial Impacts of Cancer
- Insect Pest Control Strategies
- Global Maternal and Child Health
- Pharmacology and Nanomedicine Research
- Healthcare Policy and Management
- Ethics in Clinical Research
- Interprofessional Education and Collaboration
- Women's cancer prevention and management
- Medical Imaging and Analysis
- Healthcare Systems and Challenges
University of North Carolina at Chapel Hill
2021-2025
University of North Carolina Health Care
2024
UNC Lineberger Comprehensive Cancer Center
2023-2024
Johns Hopkins University Center for AIDS Research
2024
University of the Witwatersrand
2023
University of California, San Francisco
2013-2023
San Francisco AIDS Foundation
2020-2021
Kaiser Permanente San Francisco Medical Center
2017
Kenya Medical Research Institute
2016
Kaiser Permanente
2016
Innovative strategies are urgently needed to meet the World Health Organization’s 2030 target of treating 90% women with precancerous cervical lesions, especially in countries most affected by cancer. We assessed acceptability self-administered intravaginal therapies for precancer undergoing cancer screening and treatment Kenya. conducted a cross-sectional study among aged 18 65 years or between January October 2023 Kisumu County, Participants completed questionnaire about their perceptions...
Purpose Cervical cancer disproportionately impacts women in low- and middle-income countries (LMICs). The World Health Organization’s (WHO) 90/70/90 strategy aims to eliminate cervical by 2030 increasing HPV vaccination coverage 90%, screening 70% of eligible women, effectively treating 90% those with abnormal results 2030, potentially preventing 62 million deaths LMICs. LMICs, however, struggle limited access precancer treatment, part due a lack trained professionals weak health systems....
Abstract Background The World Health Organization recommends human papillomavirus (HPV) testing for primary cervical cancer screening, including among women living with HIV (WLWH). Low-and-middle-income countries account 85% of the burden globally, yet have limited access to HPV-based largely due cost. This study aims compare performance a rapid, isothermal amplification HPV assay (ScreenFire) that Xpert detection and precancer WLWH in Malawi. Methods We utilized stored self-...
A number of challenges hinder artificial intelligence (AI) models from effective clinical translation. Foremost among these is the lack generalizability, which defined as ability a model to perform well on datasets that have different characteristics training data. We recently investigated development an AI pipeline digital images cervix, utilizing multi-heterogeneous dataset 9,462 women (17,013 images) and multi-stage selection optimization approach, generate diagnostic classifier able...
Innovative strategies are essential to meet the World Health Organization's 90/70/90 cervical cancer elimination targets, aiming for 90% access precancer treatment globally by 2030. In low-and middle-income countries (LMICs) where most cases occur, is severely limited. Scalable solutions like self-administered topical therapies can help close this gap. a recent Phase I trial (ClinicalTrials.gov NCT05362955), we demonstrated safety and adherence intravaginal 5% 5-Fluorouracil (5FU) cream as...
Abstract Purpose Innovative strategies are urgently needed to meet the World Health Organization’s 2030 target of treating 90% women with precancerous cervical lesions, especially in countries most affected by cancer. We assessed acceptability self-administered intravaginal therapies for precancer undergoing cancer screening and treatment Kenya. Methods conducted a cross-sectional study among aged 18 65 years or between January October 2023 Kisumu County, Participants completed questionnaire...
Women in low- and middle-income countries (LMICs) bear a disproportionate burden of cervical cancer, despite being preventable disease. Prevention efforts LMICs are hindered part by lack access to precancer treatment, due weak health infrastructure adequate human resources deliver current provider-administered treatments. Innovative strategies urgently needed close the treatment gap LMICs, including use self-administered topical therapies such as 5-fluorouracil imiquimod, for which efficacy...
Background: Cervical cancer continues to be a major health issue in low-and middleincome countries (LMICs).Despite increasing access screening, precancer treatment remains significant challenge LMICs, highlighting need for innovative, accessible and resource-appropriate approaches, including self-administered therapies. Methods:A cross-sectional mixed-methods study was conducted among men aged 25-65 with current female partner Kisumu County, Kenya.Participants were sequentially recruited...
Disparities in cancer research persist around the world. This is especially true global health research, where high-income countries (HICs) continue to set priorities further creating several imbalances how conducted low and middle-income (LMICs). Cancer disparities Africa can be attributed a vicious cycle of challenges ecosystem ranging from who funds conducted, conducts it, what type it disseminated. For example, funding chasm between HICs LMICs contributes inequities parachutism research....
ABSTRACT A number of challenges hinder artificial intelligence (AI) models from effective clinical translation. Foremost among these are: (1) reproducibility or repeatability, which is defined as the ability a model to make consistent predictions on repeat images same patient taken under identical conditions; (2) presence uncertainty equivocal nature certain pathologies, needs be acknowledged in order effectively, accurately and meaningfully separate true normal disease cases; (3) lack...
ABSTRACT The progression of high-risk human papillomavirus (hrHPV) to cervical cancer is well characterized, and risk factors for hrHPV including genetic predisposition, hormonal factors, host immune response, cigarette smoking are documented. Prevention primarily relies on preventing infection through vaccination, as treatment precancerous lesions (high-grade intraepithelial neoplasia [CIN2/3] or adenocarcinoma in situ [ACIS]). Bivalent, quadrivalent, nonavalent HPV vaccines prequalified by...
Abstract The World Health Organization recommends thermal ablation (TA) as an alternative to cryotherapy within “screen‐and‐treat” cervical cancer programs in low‐ and middle‐income countries (LMICs), including among women living with HIV (WLWH). Data on TA efficacy WLWH are limited, however. We conducted a clinical trial evaluate of for treatment biopsy‐confirmed intraepithelial neoplasia grades 2 3 (CIN2/3) Kenya. Nonpregnant HPV‐positive age 25 65 years underwent colposcopy‐directed...
Abstract Background Women living with HIV (WLWH), the majority of whom live in low- and middle-income countries (LMICs), are at higher risk cervical precancer, known as intraepithelial neoplasia (CIN), up to six times more likely get cancer. Current CIN treatment methods, primarily ablation or excision, have high failure rates among WLWH, 30% for grade 2 3 (CIN2/3) 24 months following ablation. Without strong follow-up many WLWH developing invasive cancer, highlighting urgent need improved...
PURPOSE The WHO now recommends thermal ablation as an alternative to cryotherapy within “screen-and-treat” cervical cancer programs in low- and middle-income countries (LMICs). We conducted a safety acceptability clinical trial of Kenyan Ministry Health hospital among women living with HIV (WLWH; ClinicalTrials.gov identifier: NCT04191967 ). METHODS Between August 2019 February 2020, WLWH age 25-65 years underwent human papillomavirus (HPV) self-collection western Kenya. HPV-positive visual...
Adjunct cervical cancer screening methods are under evaluation to improve the diagnostic accuracy of human papillomavirus (HPV)-based in low- and middle-income countries. We evaluated feasibility acceptability smartphone-based cervicography among HPV-positive women living with HIV (WLWH) Western Kenya.
Cervical cancer continues to be a major health issue in low- and middle-income countries (LMICs). Despite increasing access screening, precancer treatment remains significant challenge LMICs, highlighting need for innovative, accessible, resource-appropriate approaches, including self-administered therapies.
Abstract Background The World Health Organization (WHO) recommends human papillomavirus (HPV) testing for primary cervical cancer screening, including among women living with HIV (WLWH). Low-and-middle-income countries (LMICs) account 85% of the burden globally, yet have limited access to HPV-based largely due cost. This study aims compare performance a rapid, isothermal amplification HPV assay (ScreenFire) that Xpert detection and precancer WLWH in Malawi. Methods We utilized stored self-...
Abstract Objective To determine the safety, tolerance, and adherence to self-administered intravaginal 5% fluorouracil (5FU) cream as adjuvant therapy following cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) treatment among women living with HIV (WLWH) in Kenya. Methods A Phase I Pilot trial was performed 12 WLWH Kenya, aged 18–49 years between March 2023-February 2024 ( Clinicaltrials.gov NCT05362955 ). Participants 2g of 5FU intravaginally every other week for eight applications....